Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy BioNTech stock | $66.5
Own BioNTech stock in just a few minutes.
BioNTech SE is a biotechnology business based in the US. BioNTech shares (BNTX) are listed on the NASDAQ and all prices are listed in US Dollars. BioNTech employs 1,400 staff and has a market cap (total outstanding shares value) of USD$15 billion.
How to buy shares in BioNTech
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for BioNTech Find the stock by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$66.5, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
- Check in on your investment. Congratulations, you own a part of BioNTech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
BioNTech share price
Use our graph to track the performance of BNTX stocks over time.BioNTech shares at a glance
Information last updated 2020-09-25.
| Latest market close | USD$66.5 |
|---|---|
| 52-week range | USD$12.525 - USD$104.99 |
| 50-day moving average | USD$66.5291 |
| 200-day moving average | USD$59.3871 |
| Wall St. target price | USD$78.99 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-0.5631 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy BioNTech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioNTech price performance over time
Historical closes compared with the close of $66.5 from 2020-09-28
| 1 week (2020-09-24) | 5.84% |
|---|---|
| 1 month (2020-09-01) | 15.03% |
| 3 months (2020-07-01) | 3.68% |
| 6 months (2020-04-01) | 25.66% |
| 1 year (2019-09-27) | N/A |
|---|---|
| 2 years (2018-09-27) | N/A |
| 3 years (2017-09-27) | N/A |
| 5 years (2015-09-27) | N/A |
BioNTech financials
| Gross profit TTM | USD$91.2 million |
|---|---|
| Return on assets TTM | -16.96% |
| Return on equity TTM | -46.64% |
| Profit margin | -182.44% |
| Book value | N/A |
| Market capitalisation | USD$15 billion |
TTM: trailing 12 months
Shorting BioNTech shares
There are currently 5.1 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 33% up from 3.9 million last month.
There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.
BioNTech's "short interest ratio" (SIR)
BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 2.7 million). BioNTech's SIR currently stands at 1.87. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 1870 shares are currently held short.
However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.
Find out more about how you can short BioNTech stock.
BioNTech share dividends
We're not expecting BioNTech to pay a dividend over the next 12 months.
BioNTech overview
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc., Sanofi S.A., Genmab A/S, Genevant Sciences GmbH, Eli Lilly and Company, Bayer AG, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in Mainz, Germany.
Frequently asked questions
Ask an Expert